Your browser doesn't support javascript.
Predictors of fatal outcomes among hospitalized COVID-19 patients with pre-existing hypertension in China.
Wang, Tao; Tang, Ruidi; Ruan, Honglian; Chen, Ruchong; Zhang, Zili; Sang, Ling; Su, Xi; Yi, Shuting; Ni, Zhengyi; Hu, Yu; Liu, Lei; Shan, Hong; Lei, Chunliang; Peng, Yixiang; Liu, Chunli; Li, Jing; Hong, Cheng; Zhang, Nuofu; Zhong, Nanshan; Li, Shiyue.
  • Wang T; State Key Laboratory of Respiratory Diseases, National Clinical Research Center for Respiratory Diseases, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
  • Tang R; Guangdong Key Laboratory of Vascular Diseases, Guangzhou Medical University, Guangzhou, China.
  • Ruan H; State Key Laboratory of Respiratory Diseases, National Clinical Research Center for Respiratory Diseases, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
  • Chen R; Guangdong Key Laboratory of Vascular Diseases, Guangzhou Medical University, Guangzhou, China.
  • Zhang Z; School of Public Health, Guangzhou Medical University, Guangzhou, China.
  • Sang L; State Key Laboratory of Respiratory Diseases, National Clinical Research Center for Respiratory Diseases, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
  • Su X; State Key Laboratory of Respiratory Diseases, National Clinical Research Center for Respiratory Diseases, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
  • Yi S; Guangdong Key Laboratory of Vascular Diseases, Guangzhou Medical University, Guangzhou, China.
  • Ni Z; State Key Laboratory of Respiratory Diseases, National Clinical Research Center for Respiratory Diseases, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
  • Hu Y; Guangzhou Medical University, Guangzhou, China.
  • Liu L; Guangzhou Medical University, Guangzhou, China.
  • Shan H; Wuhan Jin-yin tan Hospital, Wuhan, China.
  • Lei C; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Peng Y; Shenzhen Third People's Hospital, Shenzhen, China.
  • Liu C; The Second Affiliated Hospital of Southern University of Science and Technology, National Clinical Research Center for Infectious Diseases, Shenzhen, China.
  • Li J; The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, China.
  • Hong C; Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, China.
  • Zhang N; The Central Hospital of Wuhan, Huazhong University of Science and Technology, Wuhan, China.
  • Zhong N; State Key Laboratory of Respiratory Diseases, National Clinical Research Center for Respiratory Diseases, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
  • Li S; State Key Laboratory of Respiratory Diseases, National Clinical Research Center for Respiratory Diseases, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Clin Respir J ; 15(8): 915-924, 2021 Aug.
Article in English | MEDLINE | ID: covidwho-1238374
ABSTRACT

BACKGROUND:

Coronavirus disease 2019 (COVID-19) is an emerging, rapidly evolving pandemic, hypertension is one of the most common co-existing chronic conditions and a risk factor for mortality. Nearly one-third of the adult population is hypertensive worldwide, it is urgent to identify the factors that determine the clinical course and outcomes of COVID-19 patients with hypertension. METHODS AND

RESULTS:

148 COVID-19 patients with pre-existing hypertension with clarified outcomes (discharge or deceased) from a national cohort in China were included in this study, of whom 103 were discharged and 45 died in hospital. Multivariate regression showed higher odds of in-hospital death associated with high-sensitivity cardiac troponin (hs-cTn) > 28 pg/ml (hazard ratio [HR] 3.27, 95% confidence interval [CI] 1.55-6.91) and interleukin-6 (IL-6) > 7 pg/ml (HR 3.63, 95% CI1.54-8.55) at admission. Patients with uncontrolled blood pressure (BP) (n = 52) which were defined as systolic BP ≥140 mm Hg or diastolic BP ≥90 mm Hg for more than once (≥2 times) during hospitalization, were more likely to have ICU admission (p = 0.037), invasive mechanical ventilation (p = 0.028), and renal injury (p = 0.005). A stricter BP control with the threshold of 130/80 mm Hg was associated with lower mortality. Treatment with renin-angiotensin-aldosterone system (RAAS) suppressors, including angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARB), and spironolactone, was associated with a lower rate of ICU admission compared to other types of anti-hypertensive medications (8 (22.9%) vs. 25 (43.1%), p = 0.048).

CONCLUSION:

Among COVID-19 patients with pre-existing hypertension, elevated hs-cTn and IL-6 could help clinicians to identify patients with fatal outcomes at an early stage, blood pressure control is associated with better clinical outcomes, and RAAS suppressors do not increase mortality and may decrease the need for ICU admission.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Hypertension Type of study: Cohort study / Observational study / Prognostic study Limits: Humans Country/Region as subject: Asia Language: English Journal: Clin Respir J Year: 2021 Document Type: Article Affiliation country: Crj.13382

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Hypertension Type of study: Cohort study / Observational study / Prognostic study Limits: Humans Country/Region as subject: Asia Language: English Journal: Clin Respir J Year: 2021 Document Type: Article Affiliation country: Crj.13382